CLSN - Celsion Corporation
| Previous Close | 2.26 |
| Open | 2.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2.16 - 2.31 |
| 52 Week Range | 0.22 - 6.06 |
| Volume | 147,447 |
| Avg. Volume | 229,761 |
| Market Cap | 39.56M |
| Beta | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT
Q4 2017 Celsion Corp Earnings Call
- Simply Wall St.•29 days ago
When Will Celsion Corporation (NASDAQ:CLSN) Become Profitable?
Celsion Corporation’s (NASDAQ:CLSN): Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.Read More...
- Zacks•4 months ago
Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
- InvestorPlace•4 months ago
FDA Win Sends Celsion Corporation (CLSN) Shares Higher
The U.S. Food and Drug Administration (FDA) has approved the company’s plans to initiate its OVATION II Study for a DNA-based immunotherapy that’s designed to locally treat ovarian cancer called GEN-1. The company’s Medical Advisory Board helped to develop the Phase I/II trial for Celsion’s drug. The upcoming Phase I/II study from Celsion will begin with a single dose escalation to a higher dose than before in order to help determine what a safe and tolerable dose of the treatment would be, including the study of how an immune system responds to such a dose.
- Zacks•4 months ago
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
- SmarterAnalyst•4 months ago
Celsion Corporation (CLSN) Shares on the Rise; Here’s Why
Celsion Corporation (NASDAQ:CLSN) investors have a smile on their faces Thursday morning, after the tiny drug maker won FDA clearance for OVATION II Study, the Company’s planned Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion CEO Michael H. Tardugno added, "GEN-1 holds the potential for tremendous promise as a cancer treatment in the rapidly emerging area of immunotherapy.
- Zacks•4 months ago
5 Breakout Stocks Offering Terrific Returns
If properly implemented, such a strategy could deliver impressive returns.
- Capital Cube•4 months ago
ETFs with exposure to Celsion Corp. : January 2, 2018
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- SmarterAnalyst•5 months ago
Here’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer
Celsion Corporation (NASDAQ:CLSN) investor sentiment is getting stoked today on back of new bullish attention from Oppenheimer analyst Hartaj Singh. Even though this biotech company has drawn some critical fire circling lead program in ThermoDox in liver cancer, what has Singh making a strong bullish case for "OPTIMA(L) redemption?"
- Benzinga•5 months ago
7 Stock's Moving In Monday's After-Hours Session
Gainers: Celsion Corporation (NASDAQ: CLSN ) shares are 18 percent higher after Oppenheimer analyst Hartaj Singh initiated coverage on the company with an Outperform rating and $9 price target. Urban Outfitters, ...
- SmarterAnalyst•5 months ago
Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study
Today, shareholders of Celsion Corporation (NASDAQ:CLSN) woke up to a nice 5% pop in the value of their shares, after the drug maker announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMT
Q3 2017 Celsion Corp Earnings Call
- Simply Wall St.•5 months ago
Is It The Right Time To Buy Celsion Corporation (CLSN)?
Celsion Corporation (NASDAQ:CLSN), a biotechnology company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last few months.Read More...
- SmarterAnalyst•6 months ago
Celsion Corporation (CLSN) Spooks Investors with a Share Dilution
Shares of Celsion Corporation (NASDAQ:CLSN) dived nearly 20% in morning trade Friday, after the drug maker's stock offering priced at a deep discount. The company said its follow-on offering of 2.64 million shares and warrants priced at $2.50, which is 13% below Thursday's closing price of $2.86. The estimated net proceeds to the Company from the sale of the shares of common stock or warrants in the registered direct offering are expected to be approximately $5.8 million.
- Zacks•7 months ago
Cancer Space Last Week Update: Pipeline Expansion in Focus
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
- Zacks•7 months ago
Celsion's Immunotherapy Candidate Impresses, Stock Surges
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.
- Capital Cube•7 months ago
ETFs with exposure to Celsion Corp. : September 18, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Zacks•8 months ago
Stocks Near 52-Week Lows: 4 Attractive Picks
Fundamentally strong stocks trading around their 52-week lows make for a great bargain, despite how weak the broader market considers them right now.
Capital Cube•8 months agoCelsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
Categories: Yahoo FinanceGet free summary analysis Celsion Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Celsion Corp. – ArQule, Inc., ImmunoGen, Inc., Endocyte, Inc., Spectrum Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., Exelixis, Inc. and Keryx Biopharmaceuticals, Inc. (ARQL-US, IMGN-US, ECYT-US, SPPI-US, ZIOP-US, EXEL-US and KERX-US) ... Read more (Read more...)
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT
Q2 2017 Celsion Corp Earnings Call
